ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

• Medical Device Clinical Trials: Key Considerations For Sponsors And CROs

  Medical device trials must align risk class, regulations, and study design. Strong oversight, data, and proactive safety planning support reliable evidence and market approval.

• Why Use Scorecards To Make Vendor Selection Decisions

  Scorecards enable structured, unbiased vendor selection by transforming complex clinical trial decisions into transparent, data-driven evaluations — ensuring operational excellence and regulatory compliance.

• Real-Time Review Is The Most Underrated FDA Story Of The Year

  The FDA’s real-time review pilot signals a massive shift in clinical operations, where continuously regulator-ready data becomes the foundation of future trial execution.

• Streamlining Trials With eConsent And EDC

  Integrating eConsent with EDC streamlines clinical workflows, improves data accuracy, and enhances patient engagement by creating a unified, compliant system for consent and trial data management.

• The Future Of Wearable Technology In Clinical Trials

  Learn how wearable technology is reshaping the future of clinical trials, offering opportunities to collect continuous, real-time health data while improving patient access and engagement.

• DTx Company Leverages Real-World Evidence Platform In Registry Study

  Discover how Castor’s eClinical system enabled a groundbreaking study in behavioral disorder treatment to collect Real-World Evidence (RWE) to support product research and claims.

• eReg Benefits For Clinical Research: Use Cases For All Types Of Sites

  Unearth the different kinds of eRegulatory use cases for diverse clinical site types and other eRegulatory capabilities designed to serve all sites.

• Timely Lab Data To Inform Outreach To Healthcare Professionals

  Learn how you can leverage a system that offers flexible data delivery formats and seamless integration into commercialization workflows while also ensuring HIPAA-compliant deidentified data for patient privacy.

• Real-World Evidence - Where Are We Now?

  Notwithstanding ongoing confusion over the concepts of “real-world data” and “real-world evidence” in 2022, more than 5 years after the passage of the 21st Century Cures Act, the FDA continues to evaluate such data and evidence as it considers regulatory decisions.

• Will DCTs Finally Democratize Clinical Trials?

  Who wouldn’t rather wear a smartwatch than drive 75 miles to have someone measure their blood pressure? See how DCTs have the capacity to include more people from a broader range of demographics.